title: Acute and chronic triptan exposure neither alters rodent cerebral blood flow nor worsens ischemic brain injury.
abstract: Although it is still debated whether vasoconstriction underlies migraine resolution by triptans, they are not recommended in patients at cardiovascular risk. However, relationship between stroke incidence and triptan use is unclear, and it is unknown whether acute or chronic use of these drugs worsens ischemic brain injury. To address this issue, we investigated the effect of clinically-relevant doses of the potent cerebral artery vasoconstrictor eletriptan on cerebral blood flow (CBF) and brain infarct volumes, as well as on expression of genes involved in cerebrovascular regulation. We report that acute treatment of rats or mice with eletriptan did not reduce basal CBF, which promptly dropped upon treatment with prazosin or dihydroergotamine. Acute of chronic (1month) eletriptan also did not affect CBF changes and infarct volumes in mice undergoing brain ischemia/reperfusion. Finally, chronic eletriptan reduced brain mRNAs for PACAP and VIP, leaving unaffected those for 5HT1B/DR and CGRP. No significant transcript changes were found in dura mater. Data suggest that the impact of triptans on cerebral hemodynamic should be re-evaluated, as well as their propensity to increase stroke risk in migraineurs.
authors: Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Italy. Electronic address: mirko.muzzi@unifi.it.
authors: Mirko
authors: M
authors: Muzzi
authors: Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Italy.
authors: Daniela
authors: D
authors: Buonvicino
authors: Headache Center, Careggi University Hospital, Florence, Italy.
authors: Francesco
authors: F
authors: De Cesaris
authors: Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Italy; Headache Center, Careggi University Hospital, Florence, Italy.
authors: Alberto
authors: A
authors: Chiarugi
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology; D002545:Brain Ischemia / Q000503:physiopathology*; D002540:Cerebral Cortex / Q000098:blood supply / Q000187:drug effects* / Q000503:physiopathology; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D004087:Dihydroergotamine / Q000494:pharmacology; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D004388:Dura Mater / Q000187:drug effects / Q000378:metabolism; D008297:Male; D008810:Mice, Inbred C57BL; D011224:Prazosin / Q000494:pharmacology; D011759:Pyrrolidines / Q000494:pharmacology*; D012333:RNA, Messenger / Q000378:metabolism; D011897:Random Allocation; D017207:Rats, Sprague-Dawley; D017366:Serotonin Receptor Agonists / Q000494:pharmacology*; D013997:Time Factors; D014363:Tryptamines / Q000494:pharmacology*; D014662:Vasoconstrictor Agents / Q000494:pharmacology
chemical_list: D000959:Antihypertensive Agents; D011759:Pyrrolidines; D012333:RNA, Messenger; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; D014662:Vasoconstrictor Agents; C115647:eletriptan; D004087:Dihydroergotamine; D011224:Prazosin
keywords: brain ischemia; cerebral blood flow; cerebrovascular disease; eletriptan; migraine